SUNPHARMA vs TATACONSUM: Stock Comparison

SUN PHARMACEUTICAL IND L vs TATA CONSUMER PRODUCTUpdated 9 Oct 26, 4:08 PM ISTNSE & company filings

SUN PHARMACEUTICAL IND L is the larger company by market capitalisation. SUN PHARMACEUTICAL IND L shows a lower P/E, a higher ROE and a higher net margin, while TATA CONSUMER PRODUCT shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

SUNPHARMA leads 8; TATACONSUM leads 5 of 13

Not a rating
These companies operate in different sectors (Healthcare vs Fast Moving Consumer Goods). Valuation and leverage norms differ across sectors, so cross-sector ratio comparisons can mislead — compare each against its own sector peers too.

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

SUNPHARMATATACONSUM

Valuation lens

What price are you paying?

Market CapContext only
₹4.22 L Cr
₹94,323 Cr
P/E RatioSUNPHARMA has the lower reading
34.85x ✓
57.69x
P/B RatioTATACONSUM has the lower reading
5.04x
4.33x ✓
EPSSUNPHARMA has the higher reading
₹12.06 ✓
₹4.31
Book ValueContext only
₹349.6
₹234.31
Dividend YieldTATACONSUM has the higher reading
0.91%
1.05% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SUNPHARMA is the larger company
₹4.22 L Cr vs ₹94,323 Cr
P/E Ratio
SUNPHARMA has a lower P/E
34.85x vs 57.69x
P/B Ratio
TATACONSUM has a lower P/B
4.33x vs 5.04x
EPS
SUNPHARMA has higher earnings per share
₹12.06 vs ₹4.31
Dividend Yield
TATACONSUM has a higher dividend yield
1.05% vs 0.91%
Revenue Growth (TTM YoY)
TATACONSUM has faster revenue growth
17.9% vs 12.8%
EPS Growth (TTM YoY)
SUNPHARMA has faster EPS growth
25.6% vs 21.5%
Qtr Sales Growth
SUNPHARMA has stronger quarterly sales growth
4.71% vs -1.56%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSUNPHARMATATACONSUM
SectorHealthcareFast Moving Consumer Goods
IndustryPharmaceuticalsTea & Coffee

Price

MetricSUNPHARMATATACONSUM
Live Price₹1,760₹955
Day Change0.01%0.33%
Volume13.46 L9.47 L
52-Week High₹2,046.9₹1,282.7
52-Week Low₹1,583.7₹945
Distance from 52W High-14.02%-25.55%

Valuation

MetricSUNPHARMATATACONSUM
Market Cap₹4.22 L Cr₹94,323 Cr
P/E Ratio34.85x57.69x
P/B Ratio5.04x4.33x
EPS₹12.06₹4.31
Book Value₹349.6₹234.31
Dividend Yield0.91%1.05%

Growth

MetricSUNPHARMATATACONSUM
Revenue Growth (TTM YoY)12.8%17.9%
EPS Growth (TTM YoY)25.6%21.5%
Qtr Sales Growth4.71%-1.56%
Qtr Profit Growth7.07%0.75%

Profitability & Leverage

MetricSUNPHARMATATACONSUM
ROE11.76%9.18%
ROCE9.6%9.64%
Net Margin18.56%7.44%
Operating Margin22.81%14.54%
Debt to Equity0.6x0.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricSUNPHARMATATACONSUM
Promoter Holding54.48%33.83%
FII Holding14.53%▼ 1.4 pp20.08%▼ 0.71 pp
DII Holding22.18%▲ 1.07 pp25.01%▲ 0.82 pp
Public Holding8.81%▲ 0.33 pp21.07%▼ 0.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SUN PHARMACEUTICAL IND L and TATA CONSUMER PRODUCT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.